Matthew Wasserman

Matthew Wasserman

Pfizer Inc. - New York / United States
Economics & Econometrics / Economics
AD Scientific Index ID: 4539163
-
person_outline Matthew Wasserman's MOST POPULAR ARTICLES
1-) Understanding the economic impact of intravascular ultrasound (IVUS)A Alberti, P Giudice, A Gelera, L Stefanini, V Priest, M Simmonds, C Lee, ...The European Journal of Health Economics 17, 185-193, 2016582016
2-) Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four …C Eckmann, M Wasserman, F Latif, G Roberts, A Beriot-MathiotThe european Journal of Health economics 14, 835-846, 2013562013
3-) Twenty-year public health impact of 7-and 13-valent pneumococcal conjugate vaccines in US childrenM Wasserman, R Chapman, R Lapidot, K Sutton, D Dillon-Murphy, ...Emerging infectious diseases 27 (6), 1627, 2021382021
4-) Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysisR Chapman, K Sutton, D Dillon-Murphy, S Patel, B Hilton, R Farkouh, ...Vaccine 38 (45), 7138-7145, 2020392020
5-) Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in CanadaM Wilson, M Wasserman, T Jadavi, M Postma, MC Breton, F Peloquin, ...Infectious diseases and therapy 7, 353-371, 2018382018